课题基金 / 基金详情

Nanoscale delivery vehicles for antigen-based vaccines

Nanoscale delivery vehicles for antigen-based vaccines
用于基于抗原的疫苗的纳米级运载工具
批准号:
7124315
负责人:
JEAN M FRECHET
金额:
$47.74万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-20 至 2009-07-31

项目摘要

项目成果

JEAN M FRECHET的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): While vaccines have been widely used for the prevention of infectious disease, the concept of therapeutic vaccination for the treatment of cancer has only recently been introduced. Although the results of animal studies suggest that this new form of immunotherapy can be highly effective, to date human cancer vaccines have shown only limited success, due mainly to inadequate potency. Two key events must occur for the induction of effective immunity to tumors: the antigens (Ags) must be delivered to dendritic cells (DCs), the most powerful antigen presenting cells known, and these cells must be activated in a manner that ensures their migration to lymphoid organs and their efficient presentation of Ag to T cells. In this proposal, we describe a new, versatile and robust chemical approach to prepare nanoparticle-based delivery vehicles for Ag-based vaccines. Our preliminary studies indicate that these nanoparticles are capable of delivering Ags to DCs in a manner that leads to potent systemic immunity. The particles include acid-labile components that have been designed such that, upon their cellular uptake and trafficking to the phagosome, they degrade readily. This induces an increase in osmotic pressure and disruption of the compartmental walls so that the encapsulated Ags are freed and delivered into the ARC cytoplasm. We propose to 1) incorporate into the nanoparticles immunostimulatory agents, in addition to Ags, that specifically activate the DCs; 2) develop new polymer scaffold and components for improved degradation kinetics and biocompatibility; 3) investigate the use of DC specific ligands and alternative routes of delivery to maximize targeting of the vaccine to DCs; and 4) evaluate the ability of our vaccine particles to induce tumor eradication in tumor bearing animals. Our ultimate goal is to create a new class of vaccines that integrates the latest developments in the fields of immunology and materials chemistry and that can be applied not only to cancer but also to a wide range of other diseases. The relevance of this research to public health lies in the development of novel therapeutic nanoparticles that can be used to create a broad range of vaccines that will activate the immune system to both protect against and combat disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microfluidic Systems with Monoliths Enabling Sample Preparation in Proteomics
Microfluidic Systems with Monoliths Enabling Sample Preparation in Proteomics
Microfluidic Systems with Monoliths Enabling Sample Preparation in Proteomics
Microfluidic Systems with Monoliths Enabling Sample Preparation in Proteomics
海外基金